Home  »  Advanced non-Hodgkin lymphoma

Advanced non-Hodgkin lymphoma

Access to genomic sequencing may lead to more accurate diagnosis at an earlier stage, as well as a greater capacity to tailor treatment for each lymphoma patient.

Lymphoma is the most common form of blood cancer in Australia, and the sixth most common cancer overall. Around 90% of lymphoma is non-Hodgkin.

Even with the best of available treatment, up to 50% of patients with high-risk advanced non-Hodgkin lymphoma will die of their disease. Access to genomic sequencing may lead to more accurate diagnosis at an earlier stage, as well as a greater capacity to tailor treatment for each patient.

It is anticipated that about half of patients tested may have genetic variants that may help guide treatment. Genomic sequencing can also provide evidence to support a patient’s pre-selection for clinical trials or compassionate drug access initiatives.

Click here for more information Melbourne Genomics' lymphoma project.